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Down-regulation of let-7 microRNA (miRNA) is a key event in lung cancer. Despite recent advances
in survival signaling, the roles of let-7 in the context of lung cancer are not fully clear. In this study,
we showed that let-7a, a member of let-7 family, negatively regulated the expression of NIRF
through NIRF 30 UTR. We also showed that NIRF was required for the let-7a-mediated elevation of
p21WAF1. These ﬁndings suggest that growth-inhibitory effect of let-7a on the A549 cells in vitro
and in vivo may be explained in part by le-7a-induced suppression of NIRF and elevation of
p21WAF1. This work reveals a novel regulatory mechanism for let-7a in the control of cellular prolif-
eration and lung carcinogenesis.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are a group of small, non-coding RNAs
that negatively regulate gene expression by imprecisely binding
to complementary sequences in the 30 untranslation region (UTR)
of their target mRNAs. Imperfect base pairing between a miRNA
and its targets suggests that miRNAs have a large regulatory
potential, and miRNAs are estimated to regulate 30% of genes in
the human genome [1]. Accumulating evidence conﬁrm that
dysregulation of miRNA expression frequently occur in various
types of cancer [2,3]. It has become increasingly clear that miRNA
abnormalities play an important role in tumorigenesis. The key to
understanding the function of these miRNAs will be identifying
and validating the targets, and further clarifying the roles of targets
in the context of human cancer.
The let-7 miRNA, the second member of miRNA family discov-
ered in 2000, was initially found to control developmental timing
in Caenorhabditis elegans [4,5]. In humans, the let-7 family, consists
of 11 related genes, has been reported to express at lower level inchemical Societies. Published by E
f Cell Biology and Medical
ical College Road, Chongqing
).lung cancer both in vitro and in vivo [6]. Reduced let-7 expression
was signiﬁcantly associated with shortened postoperative survival
and over-expression of let-7 caused the inhibition of lung cancer
cell growth in vitro, indicating a critical role of let-7 in proliferation
pathways [6]. Notably, Ras oncogene is directly regulated by let-7;
reduced expression of let-7 and concomitant enhanced expression
of Ras contribute to lung carcinogenesis [7]. Subsequently, a suc-
cession of oncogenes, including HMGA2 [8,9], c-Myc [10], NF2
[11], and several cell cycle genes (CDK6, CDC25A, and CCND2)
[12], have been shown to bemodulated directly by the let-7miRNA.
Taken together, previous studies indicate that down-regulation of
let-7 is a key event in lung cancer. Considering multiple targets
for a given miRNA, the regulatory pathways controlled by let-7
in lung cancer could be involved in a very complex network.
Although several targets for the member of the let-7 family have
been identiﬁed, our understanding for let-7 function in the context
of lung cancer is far from clear.
In this study, we utilized computational and experimental
approaches for prediction and veriﬁcation of let-7a targets. By bio-
informatics analysis, we discovered 82 potential target genes for
let-7a. We also provided strong experimental evidence that let-7a
negatively regulated the expression of NIRF (Np95 ICBP90 ring
ﬁnger) through NIRF 30 UTR. Moreover, our studies conﬁrmed that
over-expression of let-7a caused an enhancement of p21WAF1 via
the mechanism involving let-7a-mediated suppression of NIRF. Inlsevier B.V. All rights reserved.
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determined both in vitro and in vivo. Overall, these data indicate
that let-7a-mediated regulatory pathways are complex and play
a critical role in lung carcinogenesis.2. Materials and methods
2.1. Let-7a target prediction
Let-7a target site prediction was performed by using miRGen
software [13]. The intersection of the three algorithms: miRanda
(microrna.org), PicTar (4-way), TargetScans, were chosen.
2.2. Constructs, transfections, and assays
A549 cells were transfected with let-7a mimics (Shanghai
GenePharma Corp., Shanghai, China) or a mimics control, a short
double-stranded RNAs (dsRNAs) similar to Dicer-processed
miRNAs [14], using Lipofectamine 2000 (Invitrogen, CA, USA), as
previously described [15]. HeLa cells were also transfected with
let-7a inhibitor or a inhibitor control (Shanghai GenePharma Corp.,
Shanghai, China), where all the nucleotides in the inhibitors con-
tain 20-OMe modiﬁcations at every base. 48 h after transfection,
cells were harvested for Western blot analysis.
The 30 UTR of the human NIRF mRNA was cloned to pRL-TK vec-
tor (Promega, WI, USA) at the XbaI site (details shown in Supple-
mentary data). Luciferase assays were performed as previously
published protocols [14]. A549 cells or HeLa cells, seeded into
96-well plates at a density of 4  104 per well, were transfected
with a 1:7 mix (0.2 lg) of the Fireﬂy luciferase control plasmid
(pGL3-control) (Promega) and each of the Renilla luciferase con-
structs, and 0.25 ll miRNA mimics (20 lM) or miRNA inhibitor
(20 lM) with Lipofectamine 2000. After 48 h post-transfection,
cells were lysed and assayed for luciferase activities using the Dual
Glo Luciferase Assay System (Promega).
The let-7a expression construct and a control plasmid were con-
structed (details shown in Supplementary data). A549 cells were
grown in normal culture media to a 70% conﬂuent state and were
then transfected with let-7a and control expression constructs
using Lipofectamine 2000. Twenty-four hours after transfection,
cells were maintained in the growth medium containing G418
(600 lg/ml) (Amresco, OH, USA). After 7 days, monoclones were
selected for expansion to generate stable transfected cell lines that
express let-7a and the control miRNA, and named A549-let-7a cell
line and A549-control cell line, respectively. In all procedures,
G418 selection was continued.
siRNA expressed plasmids were constructed to knock down the
expression of NIRF in A549 cells (details shown in Supplementary
data). The complete coding sequence of NIRF was cloned in
between the SacI and SmaI sites of pIRES2-EGFP (Clontech, Shiga,
Japan) (details shown in Supplementary data). The pIRES2-EGFP
empty vector and pIRES2-EGFP-NIRF construct were transfected,
respectively, into A549-let-7a cells using Lipofectamine 2000.
Forty-eight hours after transfection, the cells were harvested for
Western blot analysis.
2.3. Cell culture
Human malignant cell lines A549 (lung cancer) and HeLa (cervi-
cal cancer) were grown in RPMI 1640 medium with 10% fetal bo-
vine serum in a humidiﬁed atmosphere containing 5% CO2 at
37 C. Stable transfected cell lines, A549-let-7a cells and A549-con-
trol cells were cultured in growth medium containing 600 lg/ml
G418.2.4. In vivo tumor xenograft model
BALB/C nude (nu/nu) mice (6–7 weeks old, SPF degree, 20 ± 3 g)
were purchased from Peking University Laboratory Animal Center
(Beijing, China). All animal experiments were conducted in accor-
dance with principles described in Guidelines by NIH for care
and use of experimental animals. Twenty-four nude mice were di-
vided into three groups randomly. Each group was injected subcu-
taneously in the backs with the suspension of 200 ll containing
2  106 A549 cells, A549-control cells, A549-let-7a cells, respec-
tively. The volume of xenografts was serially measured. After
30 days, the mice were sacriﬁced; the xenografts were excised
and weighed. The inhibition rates of xenografts were calculated
according to the formula: inhibition rate (%) = 1 mean weight
(A549-let-7a cells-injected group or A549-control cells-injected
group)/mean weight (A549 cells-injected group)  100%. Then,
the tumor tissue was homogenized for miRNA isolation or Western
blot analysis or immunohistochemistry detection.
2.5. Real time reverse transcription (RT)-PCR
RNA was extracted by Trizol reagent (Invitrogen). Let-7a
expression in various cells and in tumor xenografts, were mea-
sured by real time RT-PCR (details shown in Supplementary data).
2.6. Western blot analysis
NIRF, p21WAF1 and p27kip1 proteins were detected by Western
blot using anti-rabbit NIRF (Abcam, Cambridge, UK), anti-rabbit
p21WAF1 (Santa Cruz, CA, USA) and anti-rabbit p27kip1 (Santa Cruz,
CA, USA), respectively (details shown in Supplementary data).
2.7. Immunoﬂuorescence and immunohistochemistry
NIRF and p21WAF1proteins in lung cancer cells were detected by
immunoﬂuorescence, and NIRF and p21WAF1proteins in tumor
xenografts were analyzed by immunohistochemistry using
anti-rabbit NIRF (Abcam, Cambridge, UK) and anti-rabbit p21WAF1
(Santa Cruz, CA, USA), respectively (details shown in Supplemen-
tary data).
2.8. Growth inhibition test
MTT Cell Proliferation Assay Kit (Invitrogen) was used to ana-
lyze cell proliferation (details shown in Supplementary data).
2.9. Statistical analysis
The statistical analysis was performed with SPSS 11.5 software
for Windows. Results were expressed as means ± standard devia-
tion (S.D.) or means ± standard error (S.E.). Data for multiple vari-
able comparisons were analyzed by one-way analysis of variance
(ANOVA). P < 0.05 was considered to be statistically signiﬁcant.
3. Results and discussion
3.1. Bioinformatic analysis for let-7a target prediction
The purpose of computational analysis was to seek potential
targets for let-7a. miRGen [13], an integrated database, provides
the predicted target groups by using optimized combinations of
the widely used target prediction programs. To improve the accu-
racy of prediction, we chose the intersection of the three most
widespread programs: miRanda (microrna.org), PicTar (4-way),
TargetScans. As a result, we obtained 82 possible targets for let-7a
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transcription factors or are involved in transcriptional regulation.
3.2. NIRF 30 UTR contains a phylogenetically conserved binding site for
let-7a
Among these predicted candidate targets for let-7a, NIRF at-
tracted our attention due to its oncogenic property. NIRF, a mem-
ber of the UHRF (ubiquitin PHD RING ﬁnger) family, possessed
several diverse structural domains, including a NIRF_N domain, a
PHD ﬁnger, a SRA domain, and a RING ﬁnger domain (Supplemen-
tary Fig. 1A), some of which have been proved to play a critical role
in cell proliferation [16]. The NIRF gene is located in 9p23-24.1 that
is frequently ampliﬁed in many different tumors [17–19]. More
importantly, NIRF has been described to be highly expressed in
many carcinomas [20], indicating a possible role in human tumor-
igenesis. By bioinformatics analysis, a 9-nt match (nucleotides 1–9)
to the seed region at the 50 end of mature let-7a is present in the
NIRF 30 UTR (Supplementary Fig. 1B), which is considered to be re-
quired for the target recognition [21]. By analyzing homology, we
found that the putative let-7a target site in NIRF 30 UTR is highly
conserved in all four genomes, including human, mouse, rat, and
canis (Supplementary Fig. 1C). Given the analysis stated above,
NIRF was chosen for further investigation.
3.3. NIRF is a target for let-7a
To verify the targeting of endogenous NIRF by let-7a, we trans-
fected let-7a mimics or the mimics control into A549 cells, inFig. 1. Let-7a regulates NIRF expression via the NIRF 30 UTR. (A) Let-7a negatively regula
A549 cells (left) caused a signiﬁcant reduction of NIRF protein, while introduction of let
Quantiﬁcation of relative levels of NIRF protein in A549 (left) and HeLa (right) cells. Dat
treatments. (C) Luciferase activity of various reporters in the presence or absence of let-7
absence of let-7a inhibitor in HeLa cells. The ratio of reporter (Renilla lucifearse, Rn) to con
the control value from the control transfection, in which pGL3-control and pRL-TK were
percentage of the corresponding control value. Error bars (S.E.) are derived from nine exwhich let-7a is known to be poorly expressed [6,7,12]. Western
blot for NIRF protein showed that the expression level of NIRF
was reduced by approximately 50% in A549 cells transfected with
let-7a mimics, compared with untreated A549 cells (Fig. 1A and B).
No signiﬁcant differences in the levels of NIRF protein were ob-
served between the cells transfected with the mimics control and
non-transfected cells. Then, we investigated whether NIRF expres-
sion is depressed by blocking let-7a activity in HeLa cells express-
ing native let-7a. A similar approach has been used to study the
relationship between let-7 and RAS [7]. An approximately 30% in-
crease of NIRF protein level was observed in HeLa cells transfected
with let-7a inhibitor, compared to non-transfected HeLa cells
(Fig. 1A and B). These data indicate that let-7a can negatively reg-
ulate NIRF expression.
Negative regulation of NIRF protein levels by let-7a could be ex-
plained by the direct interaction between miRNA and mRNA or by
an indirect effect. Given that the 30 UTR of NIRF contains a let-7a
complementary site, we propose that this regulation is direct. To
test this, we constructed a luciferase reporter with entire human
NIRF 30 UTR and cotransfected A549 cells with each of the lucifer-
ase/NIRF 30 UTR reporters combined with either let-7a mimics or
the mimics control. As shown in Fig. 1C, transcripts carrying the
NIRF 30 UTR exhibited a >50% reduction in luciferase activity in
the presence of let-7a. In contrast, the mimics control had no sig-
niﬁcant effect on the luciferase activity (P > 0.05). These ﬁndings
suggested that 30 UTR of NIRF contained regulatory information,
allowing let-7a to regulate NIRF. In an effort to conﬁrm this, HeLa
cells were cotransfected each of the luciferase/NIRF 30 UTR report-
ers along with let-7a inhibitor or the inhibitor control. Fig. 1Dtes the expression of NIRF in A549 and HeLa cells. Transfection of let-7a mimics in
-7a inhibitor into HeLa cells (right) induced a marked increase of NIRF protein. (B)
a were expressed as means ± S.D. (n = 3). **P < 0.01 vs. corresponding cells without
a mimics in A549 cells. (D) Luciferase activity of various reporters in the presence or
trol plasmid (Fireﬂy luciferase, Ff) in relative luminescence units was normalized to
cotransfected into A549 (C) and HeLa (D) cells, respectively. All the data plotted as a
periments in triplicate. **P < 0.01 vs. the corresponding control value.
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30 UTR. Conversely, the reporter carrying the NIRF 30 UTR was only
weakly affected by the inhibitor control (P > 0.05). Our combined
results provide a strong support that 30 UTR of NIRF is indeed a tar-
get of let-7a and let-7a negatively regulates the expression of NIRF
through the NIRF 30 UTR.
3.4. Over-expression of let-7a in A549-let-7a cells and in tumor
xenografts
Stable transfected cell lines over-expressing let-7a and the con-
trol miRNA, A549-let-7a and A549-control cells, were derived from
the A549 lung cancer cell line. Real time RT-PCR displayed that let-
7a was signiﬁcantly enhanced in A549-let-7a cells compared withFig. 2. Overexpression of let-7a elevates p21WAF1 level in vitro. (A) Representative W
enhancement of p21WAF1 in A549-let-7a cells, compared with A549 cells. No signiﬁcan
expression data shown in (A). Data were expressed as means ± S.D. (n = 3). **P < 0.01, vs
A549-control and A549-let-7a cells (400). NIRF protein (top) was localized in cytopl
Quantiﬁcation of expression data shown in (C). Fluorescence intensity were evaluated fr
PLUS V6.0.0.260. Data were expressed as means ± S.D. (n = 10). **P < 0.01, vs. the A549 cuntreated A549 cells (P < 0.01, Supplementary Fig. 2A). Also, the
expression of let-7a was signiﬁcantly increased in the tumor xeno-
grafts of A549-let-7a cells-injected group compared to A549 cells-
injected group (P < 0.01, Supplementary Fig. 2B). Together, these
data demonstrated that let-7a was over-expressed in the A549-
let-7a cells by stable transfection and in the tumor xenografts of
mice injected with A549-let-7a cells.
3.5. Let-7a contributes to the restoration of p21WAF1 by targeting of
NIRF in vitro
As stated above, we veriﬁed that NIRF is a target for let-7a.
Notably, it has been reported that NIRF formed a complex with
HDAC1 (histone deacetylase 1) through its SRA domain, whichestern blot analysis demonstrating a signiﬁcant reduction of NIRF and a marked
t differences were observed in the protein levels of p27kip1. (B) Quantiﬁcation of
. the A549 cells group. (C) Immunoﬂuorescence assay of NIRF and p21WAF1 in A549,
asm and in nucleus, while p21WAF1 protein (bottom) was stained in nucleus. (D)
om 10 randomly different ﬁelds under the microscope (400) using the Image-Pro
ells group.
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presence only in the UHRF family [22]. Thus, NIRF could possibly
bind to methylated promoter regions of some tumor suppressor
genes by interaction with HDAC1 and suppress their expression
[22]. Therefore, it is tempting to speculate that over-expression
of let-7a might rescue some tumor suppressor genes via down-reg-
ulation of NIRF.
To test this hypothesis, we examined the protein levels of
p21WAF1, p27kip1, two tumor suppressor genes, highly associated
with transcriptional repression by HDAC1 [23,24]. A decrease in
NIRF and a coordinated increase in p21WAF1 were observed in
A549-let-7a cells, compared with untreated A549 cells and A549-
control cells, as tested by Western blot (Fig. 2A and B). However,
no signiﬁcant change in the levels of p27kip1was found. Similarly,
immunoﬂuorescence assay revealed that NIRF was signiﬁcantly re-
duced, whereas p21WAF1 was markedly enhanced in A549-let-7a
cells, when compared with A549 cells and A549-control cells
(Fig. 2C and D). Taken together, these ﬁndings indicate that over-
expression of let-7a in A549 cells can elevate the expression of
p21WAF1.
We next evaluated the relevance of NIRF to the let-7a-medi-
ated elevation of p21WAF1. Toward this aim, siRNA expression
vectors speciﬁc to NIRF were constructed, then transfected into
A549 cells for Western blot analysis. Reduced NIRF levels re-
sulted in a concomitant increase in p21WAF1 protein (Fig. 3A
and B). NIRF si-1 exhibited the strongest RNAi efﬁciency on NIRF
expression, and concomitantly, the most signiﬁcant increase of
p21WAF1 level was found in A549 cells transfected with NIRFFig. 3. NIRF is involved in the let-7a-mediated elevation of p21WAF1. (A) Representative W
p21WAF1 in A549 cells. (B) Quantiﬁcation of expression data shown in (A). Results were
group. (C) Representative Western blot analysis of NIRF and p21WAF1 level in A549-let-7a
Data were expressed as means ± S.D. (n = 3). **P < 0.01, compared to the untreated A549si-1, suggesting that expression level of p21WAF1 inversely corre-
lated well with NIRF. To obtain further experimental evidence
for this, we transfected pIRES2-EGFP-NIRF into A549-let-7a cells
to up-regulate NIRF expression and measured p21WAF1 protein
level by Western blot. As expected, enhanced level of NIRF
caused a decrease of p21WAF1 level (Fig. 3C and D), indicating
that increased expression of NIRF is sufﬁcient to overcome the
effect of let-7a on p21WAF1.These data strongly indicate that
NIRF is involved in the let-7a-mediated elevation of p21WAF1.
However, the exact mechanism of let-7a-mediated elevation of
p21WAF1 is not fully clear, and further studies are needed to clar-
ify the issue.
3.6. Effect of let-7a on NIRF and p21WAF1 expression in vivo
To determine the in vivo relevance of these observations, we
tested the expression of NIRF and p21WAF1 from tumor xenografts.
Consistent with results in vitro, a reduction of NIRF level and an
enhancement of p21WAF1 level were detected by Western blot in
xenografts of A549-let-7a cells-injected group, when compared
with A549 cells-injected group and A549-control cells-injected
group (Fig. 4A and B). Moreover, immunohistochemistry assay
showed similar results with decreased NIRF and increased
p21WAF1 in xenografts of A549-let-7a cells, compared with the
xenografts of A549 cells and A549-control cells (Fig. 4C and D).
These in vivo data strong support our in vitro ﬁndings that let-7a
represses NIRF expression and concomitantly elevates the expres-
sion of p21WAF1 in lung cancer.estern blot analysis demonstrating effect of NIRF siRNAs on expression of NIRF and
expressed as means ± S.D. (n = 3). **P < 0.01, compared to the untreated A549 cells
cells after up-regulation of NIRF. (D) Quantiﬁcation of expression data shown in (C).
-let-7a cells group.
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To determine the role of let-7a in cell proliferation, we exam-
ined the cell viability by MTT assay. The proliferation of A549-
let-7a cells was signiﬁcantly inhibited compared with A549 cells
and A549-control cells (Supplementary Fig. 3). The result is in
agreement with previous data [6] showing that over-expression
of let-7a suppresses growth of A549 cells in vitro. Moreover, we
evaluated the growth suppression effect of let-7a in vivo. A signif-
icant depress in tumor weight was observed in the xenografts of
A549-let-7a cells-injected group, compared with A549 cells-in-
jected group and A549-control cells-injected group (Supplemen-
tary Table 2). These data conﬁrm that over-expression of let-7a
inhibits the growth of A549 lung cancer cells in vitro and in vivo.
In recent years, the roles of let-7 in lung cancer have received
much attention of the investigators, and down-regulation of let-7
was recognized as a key event in the pathogenesis of lung cancer.Fig. 4. Effect of let-7a on the expression of NIRF and p21WAF1 in vivo. (A) Representati
marked increase of p21WAF1 protein in xenografts of A549-let-7a cells-injected group, com
in (A). Data were expressed as means ± S.D. (n = 3). **P < 0.01, vs. A549 cells-injected g
(200). (D) Quantiﬁcation of expression data shown in (C). The average gray value was m
Image-Pro PLUS V6.0.0.260. Data were expressed as means ± S.D. (n = 10). **P < 0.01, vs.Supporting the relevance of this is the fact that some oncogenes
were discovered to be negatively regulated by let-7, of which the
ﬁrst one is Ras oncogene [7]. The 30 UTR of Ras contains multiple
let-7 complementary sites, allowing let-7 to regulate the expres-
sion of Ras. HMGA2 was subsequently proved to be a regulatory
target of let-7 [8]. The suppression of HMGA2 by let-7 was depen-
dent on multiple let-7 complementary sites in the 30 UTR of
HMGA2, and the growth-inhibitory effect of let-7 on lung cancer
cells was relieved by over-expression of HMGA2 [9]. In addition,
c-Myc [10] and a few cell cycle oncogenes, including CDK6,
CDC25A and CCND2 [12], have been reported to be modulated di-
rectly by let-7 through the 30 UTR of these oncogenes. Overall, de-
crease of le-7 and the corresponding increase of these target
oncogenes may contribute to survival signal in lung cancer.
Although several oncogenes mentioned above have been re-
ported to be regulated directly by the let-7 miRNA, it is not elimi-
nated that other genes may also be targeted by let-7. Our resultsve Western blot analysis showed that a signiﬁcant decrease of NIRF protein and a
pared with A549 cells-injected group. (B) Quantiﬁcation of expression data shown
roup. (C) Immunohistochemistry assay of NIRF and p21WAF1 in tumor xenografts
easured from 10 randomly different ﬁelds under the microscope (200) using the
A549 cells-injected group.
X. He et al. / FEBS Letters 583 (2009) 3501–3507 3507strongly indicated that NIRF is also a target for let-7a, and the
growth inhibition effect of let-7a could be explained in part by
le-7a-mediated suppression of NIRF and elevation of p21WAF1.
The present data conﬁrm that the biological pathways controlled
by let-7a in lung cancer are involved in a very complex and intri-
cate regulatory network.
In conclusion, we demonstrate that over-expression of let-7a
elevates p21WAF1 protein level by targeting of NIRF in lung cancer.
Therefore, decreased expression of let-7a induced an enhancement
of NIRF and a reduction of p21WAF1, and thereby may contribute to
lung carcinogenesis. Further investigations are required, including
a large number of predicted targets for let-7a. And more work is
essential for understanding the crosstalk of the regulatory network
controlled by let-7a in lung cancer.
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